In the #biotech #stocks #NGS field, there is a company that's recently IPOed and has now presented an update of their plans: $OMIC Singular Genomics @SingularGenomi1 investor.singulargenomics.com/static-files/0…
Their two planned instruments, the G4 and the PX, look physically a lot like competitors to the #Illumina NextSeq and NovaSeq, or the #MGI #DNBSEQ G400 and T7 instruments. But the PX is more of a multi-omics play rather than a higher throughput #NGS machine.
It seems we are about 1 year or 1.5 years away from Early Access / Commercial Launch for the PX, maybe around 6 months earlier for the G4 instrument.
The tech highlights for the G4 are: faster cycle times, 100-fold better accuracy, and max read length of 100-150bp, and an "SLR" read length of circa 3000 bases. I think SLR here means the equivalent of the #DNBSEQ Single Tube Long Fragment Read (stLFR)
In terms of accuracy, it would mean that Q50 is the new normal, rather than 10x lower accuracy (Q40) or 100x lower accuracy or Q30 which is the Illumina / MGI benchmark.
They present what their stLFR equivalent, SLR, looks like for 1400 Base Fragment Reconstruction.
The two beta sites are getting either the specced 150M reads or a bit below that. These are available in the #NGS #specs page bit.ly/ngsspecs
The PX is a multi-omics machine: a mish-mash of #singlecell, #ngs, multiplexed #imaging and #proteomics
The G4 launch is expected to be in about 6-9 months time
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.